clinical trial · NCT02759419
A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.
Bayer·phase4·completed·n = 18
Hypertension, PulmonaryAdempas (Riociguat, BAY63-2521)
brief summary
To provide riociguat therapy to eligible patients with PAH originating from Bayer-sponsored trials with BAY63-2521/ Riociguat / Adempas® who are currently or recently treated in these trials until lack of patient benefit as assessed by investigator, or commercial availability and reimbursement.
started
Jun 16, 2016
primary completion
Sep 15, 2025
completion
Sep 15, 2025
last updated
Oct 3, 2025
official title
An Open-label, Multi-national, Multi-center, Single-arm, Uncontrolled, Long-term Extension Study of Orally Administered Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH) Who Received Riociguat in a Bayer Clinical Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol